Back to results
US 2023/0026163 A1Published application
Anticancer compound and medical use thereof
AssigneeAscentawits Pharmaceuticals, Ltd.
InventorsAnrong LI, Jianxin DUAN, Fanying MENG, Xiaohong CAI
Life of this patent
Estimating the term…
Abstract
A compound of formula (I), or pharmaceutically acceptable salts, solvates, isotopic variants, or isomers thereof, and anticancer medical use are provided.
Claims25
A compound of formula (I), or a pharmaceutically acceptable salt, a solvate, an isotopic variant, or an isomer thereof:
- wherein
- Cx is a 5- to 10-membered aryl ring or heteroaryl ring, a heteroaliphatic ring or a cycloalkane, and the Cx shares two carbons with the nitrobenzene ring to form a fused ring structure;
- R1 is attached to any skeleton atom of the Cx ring, and the R1 is selected from a hydrogen, a halogen atom, a cyano or isocyano group, an hydroxyl group, an thiol group, an amine, an OTs, a C1-C6 alkyl group or a Z-substituted alkyl group, a C2-C6 alkenyl group or a Z-substituted alkenyl group, a C2-C6 alkynyl group or a Z-substituted alkynyl group, a C3-C8 cycloalkyl group or a Z-substituted cycloalkyl group, a C6-C10 aryl group or a Z-substituted aryl group, a 4- to 15-membered heterocycle or a Z-substituted heterocycle, a 5- to 15-membered heteroaryl group or a Z-substituted heteroaryl group, an alkoxyl group with 1-6 carbon atoms or a Z-substituted alkoxyl group with 1-6 carbon atoms, —CONR6R7, —SO2NR6R7, —SO2R6, —OCOO—R6, —COOR6, —NR6COR7, —OCOR6, —NR6SO2R7, or —NR6SO2NR6R7;
- R2 and;
- R3 are each respectively a hydrogen, a C1-C6 alkyl group or a Z-substituted alkyl group, a C2-C6 alkenyl group or a Z-substituted alkenyl group, a C2-C6 alkynyl group or a Z-substituted alkynyl group, a C3-C8 cycloalkyl group or a Z-substituted cycloalkyl group, a C6-C10 aryl group or a Z-substituted aryl group, a 4- to 15-membered heterocycle or a Z-substituted heterocycle, a 5- to 15-membered heteroaryl group or a Z-substituted heteroaryl group, or a 3- to 6-membered ring formed by R2, R3, and the bonded carbon atom at the benzylic position;
- group replaces a hydrogen atom at any position on a carbon atom of the fused ring, and a number of substitutions is 1;
- the Z-substituted group is a halogen atom, a cyano or isocyano group, a hydroxyl group, a thiol group, an amine group, a C1-C3 alkyl group or a substituted alkyl group, a C1-C3 alkoxyl group or a substituted alkoxyl group, a C2-C3 alkenyl group or a substituted alkenyl group, C2-C3 alkynyl group or a substituted alkynyl group, or a C3-C8 cycloalkyl group or a substituted cycloalkyl group;
- R6 and R7 are each respectively a hydrogen, a C1-C6 alkyl group or a Z-substituted alkyl group, a C2-C6 alkenyl group or a C2-C6 Z-substituted alkenyl group, a C2-C6 alkynyl group or a Z-substituted alkynyl group, C3-C8 cycloalkyl group or a Z-substituted cycloalkyl group, a C6-C10 aryl group or a C6-C10 Z-substituted aryl group, a 4- to 15-membered heterocylic group or a Z-substituted 4- to 15-membered heterocyclic group, 5- to 15-membered heteroaryl group or a Z-substituted 5- to 15-membered heteroaryl group, or a 5- to 7-membered heterocyclic group or a Z-substituted 5- to 7-membered heterocyclic group formed by R6, R7, and an atom bonded thereto.
5 more elements
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a subject to a primary brain cancer, a brain tumor, or a metastatic cancer or a tumor metastasizing to a brain, the method comprising:
- preparing a drug with a compound of the following formula;
- and
- administering to the patient the drug;
Dependencies are inferred from the claim text.